Biolipox continues the clinical development of a new hay fever treatment
Biolipox continues the clinical development of a new hay fever treatment Biolipox, a pharmaceutical research and development company in respiratory and inflammation has decided to continue the clinical development of a nasal spray for the treatment of both allergic and non-allergic rhinitis. The decision was taken following the successful completion of clinical Phase I, showing good tolerability of the drug in healthy volunteers. The results from the ongoing Phase IIa study will be available in mid 2004. The world wide rhinitis market is valued at more than US$ 8 billion. Thirty-six